Table 3.
Univariate analysis of factors affecting CD34 mobilization yields
| Covariate | F value | P value |
|---|---|---|
| Weight of donor | 1.50 | .23 |
| Age of donor (younger) | 6.02 | .020 |
| Sex of donor (male) | 4.07 | .052 |
| Baseline CD34 (high) | 14.94 | .0005 |
| Statin use by donor | 3.01 | .093 |
| % pDC in product | 14.24 | .0007 |
| CXCL12 at baseline | 1.15 | .29 |
| Change CXCL12 baseline to 30 min | t = 3.05 | .0048 |
| CXCL12 SNP genotype | 1.37 | .27 |
| Diabetes in donor | 0.87 | .36 |
| Hypertension in donor | 0.02 | .89 |
| Baseline platelets | 5.85 | .022 |
| Baseline WBC | 0.05 | .83 |
| Tobacco use by donor | 0.18 | .84 |
| Cmax of plerixafor | 3.19 | .084 |
| AUC of plerixafor | 3.70 | .064 |
A repeated measures regression model of CD34/L undergoing apheresis day 1 transformed to log10 by demographic and clinical variables was performed. Cellular mobilization over time was analyzed by mixed models (transformation shown in parentheses) specifying patient as a random effect and modeling the outcome of CD34/L day 1 on a log10 scale.
SNP, single-nucleotide polymorphism; WBC, white blood cell.